29 June 2018

Contents

Editorial

• 29 June 2018: vol 19 no 11: darunavir/cobicistat alert and PK reports

Treatment alerts

• New contraindication against using darunavir/cobicistat during pregnancy

• Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Conference reports

• 19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore

• Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model

• Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole  

• Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network  

• Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults 

• No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin  

• Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin

• Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort

Antiretrovirals

• China approves albuvirtide: a once-weekly injectable entry inhibitor

• Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance

Coinfections and complications

• RITA: issue on lung health

HIV prevention and transmission

• New FDA guidance for developing PrEP drugs

• UK PrEP IMPACT trial announces 3000 new places for gay men but low uptake by women, African and transgender people

Cure research

• Cure research: open access publications

On the web

• US community call for coalition for long-term survivors

PDFs

• 29 June 2018: vol 19 no 11